![](https://ml.globenewswire.com/media/0a0cee04-abf8-4e73-bc2b-beede3c3f9d8/small/marius-logo-cmyk-no-background-png.png)
Marius Pharmaceuticals Submits KYZATREX® (Testosterone Undecanoate) CIII Capsules for Approval to Health Canada
RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, a patient-centric healthcare company focused on developing innovative therapies for Testosterone Deficiency, is pleased to announce the submission of its New Drug Submission (NDS) for …